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ABSTRACT 
The effects of alcohol use in non-alcoholic fatty-liver disease are unclear. We investigated 
the impact of alcohol use in fatty liver disease on incident liver, cardiovascular, and 
malignant disease, and death. Study comprised 8345 persons with hepatic steatosis (fatty-
liver index >60) who participated in the health-examination surveys (FINRISK 1992-2012 or 
Health 2000), with available data on baseline alcohol intake. Main exclusions were baseline 
clinical liver disease, viral hepatitis, ethanol intake >50g/day, and current abstainers. Data 
were linked with national registers for hospital admissions, malignancies and death regarding 
liver, cardiovascular, and malignant disease, and all-cause death. Adjustment were for 
multiple confounders. Alcohol consumption showed a dose-dependent risk increase for 
incident advanced liver disease and malignancies. Consuming 10-19g/day of alcohol in 
general, or 0-9g/day as non-wine beverages, doubled the risk for advanced liver disease 
compared to lifetime abstainers. In contrast, alcohol intake up to 49g/day was associated with 
a 22-40% reduction of incident CVD. We observed a J-shaped association between alcohol 
intake and all-cause death with a maximal risk reduction of 21% (95%CI 5-34%) at alcohol 
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intake of 0-9g/day compared to lifetime abstainers. However, these benefits on CVD and 
mortality were only observed in never smokers. Alcohol intake above 30g/day yielded 
increased risk estimates for mortality compared to lifetime abstainers. In a subpopulation 
with longitudinal data, alcohol intake remained stable over time in >80% of subjects. 
 
Conclusion: Even low alcohol intake in fatty liver disease is associated with increased risks 
for advanced liver disease and cancer. Low to moderate alcohol use is associated with 
reduced mortality and CVD risk, but only among never smokers. 
 
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in 
Western countries with around 25% of the adult population affected (1). NAFLD 
encompasses a spectrum from simple accumulation of fat in the liver (steatosis) to 
steatohepatitis, fibrosis, liver cirrhosis, and hepatocellular carcinoma, with only a fraction of 
NAFLD patients developing advanced liver disease. The condition is interlinked with 
features of the metabolic syndrome including obesity, insulin resistance, type 2 diabetes, and 
atherogenic dyslipidemia. Paralleling the worldwide increase of obesity and the metabolic 
syndrome, NAFLD is rapidly becoming the leading indication for liver transplantation and a 
major cause for liver cancer (2).  
 
Although heavy alcohol intake has many detrimental effects on health, epidemiological data 
link light to moderate drinking with reduced cardiovascular mortality in the general 
population (3, 4). Cardiovascular disease is the most common cause of death in NAFLD (5), 
but it remains unclear whether the proposed cardiovascular benefits of light alcohol use 
extend to individuals with NAFLD (without cirrhosis). Furthermore, even minimal alcohol 
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consumption has been linked to an increased risk for certain cancers (6, 7), and cancer is 
another leading cause of death in NAFLD (5). 
 
Whether light to moderate alcohol use affects progression of NAFLD is also unclear (8). 
NAFLD is currently separated from alcoholic liver disease by an arbitrary daily alcohol 
intake of 30 g for men and 20 g for women, under the assumption that alcohol intake below 
these thresholds is insufficient to induce hepatic steatosis (9-11). Evidence from some studies 
even point to liver protective effects of light to moderate alcohol consumption in form of a 
reduced prevalence of NAFLD and liver fibrosis (12-16). These studies, however, are cross-
sectional, use surrogate end points, are typically based on selected patients, and are limited by 
incomplete adjustment for confounders. Many studies failed to consider the pattern and type 
of alcohol use in addition to average alcohol intake, and did not separate between lifetime 
abstainers and current abstainers, the latter of which may be enriched in former heavy 
drinkers. In addition, with regard to the risk for advanced liver disease, prospective studies 
from the general population suggest that no safe limit of alcohol use exists (17, 18). 
 
Potential benefit and harm of light to moderate alcohol use in NAFLD is therefore currently 
unclear. Therefore, no evidence-based recommendations can currently be given on how to 
counsel patients with NAFLD regarding alcohol use (8, 19). This is an important issue given 
that the majority of subjects with NAFLD do consume some amount of alcohol (20, 21). 
 
We analyzed the effect of various levels of alcohol intake on the risk for development of 
advanced liver disease, cardiovascular disease, malignancies, and all-cause death among 
individuals with fatty liver disease in a large general population cohort with linkage to 
national health-care registries. 
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Materials and methods 
Cohorts 
Baseline data were extracted from the population-based National FINRISK Studies from 
1992, 2002, 2007, and 2012, and the Health 2000 survey from 2000-2001 (22, 23). The 
FINRISK studies are cross-sectional population surveys carried out in Finland in a systematic 
and standardized fashion every 5 years since 1972 by the National Institute for Health and 
Welfare (previously National Public Health Institute), to assess risk factors for chronic 
diseases in representative population samples of adults aged 25-74 years (FINRISK 1992: 25-
64 years) drawn from the Finnish Population Information System, stratified by sex, 10-year 
age groups, and 4-6 geographical areas of Finland. Number of invitees have varied over years 
from 7927 to 13498, and participation rates from 57% to 94% (23). 
 
The Health 2000 Survey was also coordinated by the National Institute for Health and 
Welfare (previously National Public Health Institute), and originally comprised 8028 adults 
aged 30 years and over; participation rate in the full examinations was 80% (22). The cohort 
is considered representative of the entire Finnish population through a regional two-stage 
stratified cluster sampling procedure.  
 
The methods, measurements and protocols used in the FINRISK studies have been essentially 
the same over time and are similar to those in the Health 2000 Survey (22, 23). Data were 
collected from each participant at baseline via interviews (Health 2000), questionnaire and 
health examination by trained physicians and nurses (Health 2000) and trained nurses 
(FINRISK) using standardized procedures of the MONICA (24) and European Health Risk 
Monitoring projects (25). Blood samples collected at baseline for a wide spectrum of 
laboratory measurements were handled using a standardized protocol. Detailed descriptions 
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of study protocols have been published previously (22, 23). All participants provided signed 
informed consent, and the studies were approved by the Coordinating Ethical Committee of 
the Helsinki and Uusimaa Hospital District (previously studies also approved by the 
institutional review board of the National Public Health Institute). 
 
Participants 
The present study included individuals with fatty liver disease, defined as a fatty liver index 
(FLI) ≥60 (26), and with available data on alcohol use. A description of the FLI is found in 
supplementary data. We excluded individuals with a baseline diagnosis of chronic liver 
disease (ICD10: K70-K77, C22.0; ICD8/9: 570-573, 155.0), chronic viral hepatitis at 
baseline or during follow-up (ICD10: B18), current alcohol abstainers (had used alcohol 
earlier and then stopped), and subjects reporting to consume more than 50 g ethanol/day 
(Figure 1). NAFLD is usually differentiated from alcoholic fatty liver disease by an arbitrary 
limit of daily alcohol intake of 30 g for men and 20 g for women. As this limit is based on 
minimal evidence, we extended the limit to include up to 49 g to allow for a more 
comprehensive picture of the impact of alcohol. 
 
Baseline data 
Respondents were asked to report how often they consumed alcoholic beverages during the 
previous year and the average amount they consumed per week during the previous month. 
Average alcohol intake (grams per day) was calculated as the sum of the daily number of 
drinks multiplied by the average alcohol content per type of alcoholic beverage. The fraction 
of wine consumption of total alcohol use was assessed separately. Participants were also 
asked if they had been abstinent their entire life (lifetime abstainer) or had used alcohol 
earlier and then stopped (current abstainer). Binge drinking was defined as drinking 5 or 
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more alcohol drinks per occasion, in line with previous studies (27, 28). Respondents 
reported the number of times during the last 12 months that they consumed 5 or more drinks 
per occasion.  
 
Current and previous use of acetylsalicylic acid (ASA) was inquired. Exercise was assessed 
by asking how often the subject performs leisure-time physical exercise for at least 20-30 
minutes so that he/she is at least slightly out of breath and sweaty. Diabetes was defined 
either by a fasting serum glucose ≥7.0 mmol/L (126 mg/dL), taking diabetic medication, or 
by having a prior known diabetes diagnosis. Baseline cardiovascular risk was calculated by 
the Finrisk score (see supplementary data). 
 
Follow-up data 
Follow-up data for hospitalizations were obtained from the National Hospital Discharge 
Register (HILMO), which covers all hospitalizations in Finland since 1969. One or several 
ICD-diagnoses are assigned to each hospitalization at discharge; these diagnosis codes are 
systematically recorded in the National Hospital Discharge Register. Data for malignancies 
were obtained from the Finnish Cancer Registry, with nationwide cancer records since 1953. 
Vital status and the cause of death data were obtained from Statistics Finland, which 
systematically collects data about the deaths of all Finnish citizens. In Finland, each person 
who dies is by law assigned a cause of death (in accordance with the International 
Classification of Diseases, ICD) to the official death certificate, issued by the treating 
physician based on medical or autopsy evidence, or forensic evidence when necessary; the 
death codes are then verified by medical experts at the register and recorded according to 
systematic coding principle. Data collection to all these registries is mandatory by law and 
general quality is consistent and complete (29). Linkage was performed using the unique 
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personal identity code assigned to all Finnish residents. Follow-up for deaths and 
hospitalizations were until December 2013 and for cancers until December 2012, or until 
emigration. With the help of these nationwide registers, the follow-up is virtually 100% 
complete. 
 
Outcomes 
Study end-points were fatal and non-fatal advanced liver disease (requiring hospital 
admission or causing liver cancer or liver-related death), cardiovascular disease (CVD) 
events, cancer, and all-cause death. The ICD-codes used for defining these various end-points 
are listed in Supplementary table 1. Hospital admission due to liver disease means that a 
liver-related complication was the main cause or a highly relevant contributing cause of 
hospitalization. A breakdown of ICD-codes for hospital admissions are shown in 
Supplementary figure 2. 
 
Subpopulation with follow-up data on alcohol intake 
To study stability of alcohol intake over time, we performed a subpopulation analysis on 
general population subjects who by chance had participated in two different surveys. Here we 
included subjects regardless of the FLI, but otherwise with the same study inclusion and 
exclusion criteria. Pearson correlation was used for testing a potential association between 
baseline FLI and a change in alcohol intake by >10 g/day at follow-up.  
 
Statistical analyses 
For comparing groups, we used Chi Square or Mann Whitney tests as appropriate. Average 
alcohol intake was divided into the following strata: lifetime abstainers, 0-9, 10-19, 20-29, 
30-39, 40-49 g/day. Trends in baseline characteristics across alcohol strata were tested, for 
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continuous variables, by the Jonckheere-Terpstra-test, and, for categorical variables, by the 
linear-by-linear-test. Baseline predictors of outcome events were estimated by adjusted 
hazard ratios (HR) with 95% confidence intervals (CI) using Cox proportional hazards 
models with time to first event as the outcome variable. Several multivariate models were 
constructed separately for each outcome with various level of adjustment (please see 
supplementary data for a detailed description of multivariate analyses). The proportional 
hazards assumption of the Cox model was checked using Schoenfeld residuals, and no 
violations were detected. The relationship between average alcohol use and the various 
outcomes was examined using the penalized spline smoothing method (30) with multivariate 
adjustment. Individuals with baseline CVD or cancer were excluded from the analyses that 
looked at these outcomes. Subgroup analyses were by age tertiles, gender, calender-time 
period, wine intake, diabetes status, smoking status (current, former, never), and binge 
drinking habits (excluding subjects reporting 5 drinks per occasion at least once monthly). 
Separate analyses were performed with death at age <75 years (premature death) or more 
severe forms of liver disease as the outcome (supplementary data). Effect modification of the 
FLI for the association between alcohol use and liver-disease risk was analyzed in the overall 
cohort of 27774 individuals (Figure 1) in 3 strata: FLI <30 (no steatosis), 30-59 (possible 
steatosis), and ≥60 (steatosis). P-values <0.05 were considered statistically significant. Data 
were analyzed with SPSS version 23 and R software version 3.2.5. 
 
Results 
The study comprised 8345 individuals with fatty liver disease, 5048 men and 3297 women 
(Table 1). There were significant differences between men and women for all the baseline 
variables except for exercise habits, systolic blood pressure, total cholesterol, and LDL 
cholesterol level (Table 1). We observed significant trends across strata of average alcohol 
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intake for all baseline variables except for the fraction of wine consumption, total cholesterol, 
LDL cholesterol, and family history of CVD or cancer (Supplementary table 2). In particular, 
lifetime abstainers were on average older, more often women, in lower educational groups, 
less often smokers, and exhibited higher 10-year risk for CVD (17% among abstainers vs 7.8-
10% in the various alcohol strata) as calculated by the Finrisk score (Supplementary table 2). 
 
The mean follow-up time until death or end of follow-up was 11.1 years (SD 5.9, range 0-
23.0), yielding 92350 person-years of follow-up. During follow-up, we observed 152 events 
of incident advanced liver disease (admission, liver cancer or death), 1003 incident CVD 
events, 794 incident cancers, and 1142 deaths. Among men, the respective number of 
observed liver events, CVD events, cancers and deaths were 94, 680, 489, and 718, and 
among women, 58, 323, 305, and 424.  
 
Table 2 shows the number of outcome events, age-adjusted incidence rates and adjusted HRs 
for the four different outcomes across strata of alcohol intake. Figure 2 shows the association 
between average alcohol intake and the risk for the four outcomes separately for men and 
women. Even low alcohol use (0-9 g/day) produced elevated HRs for incident liver disease 
compared to lifetime abstainers, but these estimates became statistically significant at an 
alcohol intake of 10-19 g/day (Table 2). 
 
Low alcohol use (0-9 g/day) was also associated with an increased risk for incident cancer 
compared to lifetime abstainers (Table 2), with borderline significance in multivariate 
analyses. At alcohol intake above 30 g/day the increased risk for cancer was significant in all 
multivariate models (Table 2 and Figure 2). 
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Alcohol intake up to 49 d/day was associated with reduced risks for incident CVD events 
with the risk reduction varying by alcohol strata from 22-40% in the fully adjusted model 
(Table 2 and Figure 2). 
 
We observed a J-shaped association between alcohol intake and all-cause death with a 
maximal risk reduction of 21% at alcohol intake of 0-9 g/day in the fully adjusted model 
(Table 2). With alcohol intake above 30 g/day, the risk of death tended to increase along with 
rising alcohol consumption above that observed in lifetime abstainers in all models and 
among both men and women (Table 2 and Figure 2). 
 
Effect modification of wine  
The effect of alcohol intake of 0-24 g/day on the risk for incident CVD was sensitive to the 
fraction of wine intake with a larger risk reduction seen in preferential wine drinkers as 
compared to lifetime abstainers (Figure 3). A similar trend was seen for all-cause death. In 
addition, whereas consumption of non-wine alcohol beverages of less than 25 g/day raised 
the risk for liver events 2.1-fold compared to lifetime abstainers, low preferential wine 
drinking exhibited non-significant risk estimates for liver disease (Figure 3). In contrast, low 
drinking raised the risk for cancer without any clear effect modification from the fraction of 
wine.  
 
Alcohol intake of 25-49 g/day was associated with increased risks for liver disease and 
cancer regardless of the fraction of wine, and an increased risk for death in preferential non-
wine drinkers (Figure 3). 
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Subgroup analyses  
Risk estimates for low alcohol use were increased in the lowest age tertile compared to the 
middle and highest tertiles (Supplementary table 3). There was no evident effect modification 
of age for other outcomes. 
 
With regards to smoking status, the reduced risks for CVD and mortality with low alcohol 
use was evident only among never smokers (Supplementary table 3), a finding confirmed in 
multivariate-adjusted analysis (Figure 4). The alcohol-related risk increase for cancers was 
accentuated among current smokers (Supplementary table 3). 
 
We observed no major effect modification by diabetes status or binge drinking status on the 
HR estimates for each outcome across strata of average alcohol intake (Supplementary table 
3). The effect of alcohol on cancer risk was more evident in older cohorts (Finrisk 1992 and 
2002 and Health 2000), where the follow-up was longer and number of events higher 
(Supplementary table 3). 
 
Findings were practically unaltered when considering premature death as the outcome 
(Supplementary table 5), or when restricting liver outcomes to ICD-codes reflective of liver 
cirrhosis, liver dysfunction or equivalent (Supplementary table 6). 
 
Effect modification of the FLI 
In the overall cohort of 27774 individuals, we found a steeper increase in the adjusted HRs 
for liver disease in the higher FLI groups at any given level of alcohol use (Supplementary 
figure 1), suggesting increased harm from alcohol in the presence of fatty liver disease. 
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Stability of alcohol intake over time  
Among 492 subjects (mean age 47 years, women 53%) who had participated in two different 
surveys at an average 9.0 years (SD 4.6) apart, mean daily alcohol intake changed from 7.2 
g/day (SD 9.4) to 10.2 g/day (SD 18.0) (P=0.30). Percentage wine consumption of total 
alcohol consumption increased from 26% to 33% (P<0.001).  
 
Alcohol intake remained stable in 373 (82%) subjects, increased by >10 g/day in 57 (13%), 
and decreased by >10g/day in 27 (6%). All lifetime abstainers remained either abstainers or 
drank <10 g/day at follow-up. Among those consuming 0-9 g/day, alcohol use remained 
stable in 91%. In contrast, among those with baseline alcohol intake >30g/day, 48% had 
reduced their alcohol intake by >10 g/day at follow-up. We found no significant correlation 
between baseline FLI and the change in alcohol consumption over time (P=0.83). 
 
Discussion 
This study analyzes the associations between alcohol and incident liver disease, CVD, cancer 
and all-cause mortality specifically in persons with a fatty liver. We found no benefits from 
low alcohol intake with regards to the risk for advanced liver disease in such persons. While 
there was no appreciable liver harm from consuming one glass of wine per day, even low 
consumption of non-wine beverages doubled the risk for liver disease. Consuming more than 
10 g/day of alcohol increased the risk for liver disease in a dose-dependent fashion regardless 
of the level of adjustment for confounders. In addition, moderate alcohol intake, and with 
borderline significance also low alcohol intake, whether wine or non-wine, tended to increase 
the risk for cancers in both men and women. 
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Alcohol consumers had a consistently lower risk for incident CVD than lifetime abstainers, 
an effect most obvious in the fully adjusted multivariate model. We observed a J-shaped 
relationship between alcohol use and all-cause mortality with a maximal risk reduction of 
21% at alcohol intake of 0-9 g/day in the fully adjusted model. Larger risk reductions for both 
death and CVD were seen in preferential wine drinkers than in non-wine drinkers. Alcohol 
intake above 30 g/day was associated with increased mortality. However, the J-shaped 
relationship between alcohol and mortality was only evident in never smokers. 
 
Strengths of our study include the large and well-characterized population-based cohorts of 
men and women with longitudinal follow-up and hard endpoints (hospital admission, cancer, 
death) from reliable national registries. We were able to adjust for multiple acknowledged 
confounders (3, 31). Additional strengths include the ability to account for wine intake and 
binge drinking, and exclusion of current abstainers, which may be enriched with former 
heavy drinkers and more co-morbidity (32, 33). By exclusion of cases with chronic viral 
hepatitis at baseline or during follow-up we avoided confounding impact of these factors.  
 
Underreporting alcohol use and recall bias is a concern in any observational study, but more 
so when data is collected in liver clinics from patients with known liver disease where 
awareness of the liver condition may affect patient responses (8). In contrast, because the 
majority of subjects in our study were likely unaware of having a fatty liver, bias from 
intentional underreporting alcohol consumption is likely considerably lower in this setting. 
Recall bias is still a concern since respondents were asked to recall the frequency of alcohol 
use during the previous year. Underreporting alcohol use would tend to bias the risk estimates 
toward the null hypothesis, which is less of an issue when the risk estimates, as in our study, 
are significantly elevated.  
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A major study limitation is that alcohol habits were assessed only once, during the previous 
year. However, we were able to analyze changes over time in alcohol use in a subpopulation, 
and found that 82% had stable alcohol consumption over time. As in previous studies (34, 
35), we found that drinking habits remained much more stable in low and moderate drinkers 
than in heavy drinkers, with more than 90% of those consuming alcohol 0-9 g/day remaining 
in the same consumption category.  
 
Despite a large number of factors adjusted for in multivariate analyses, residual uncontrolled 
confounding may exist. For instance, wine drinkers may exhibit a healthier lifestyle profile, 
such as eating healthier food (36)  and more often being nonsmokers. However, such 
uncontrolled confounding could be reasonably minimized by adjusting for a wide variety of 
factors that are also affected by the same lifestyle habits, such as obesity, blood pressure, 
cholesterol and triglyceride levels and diabetes, as well as socioeconomic status. Indeed, 
adherence to a healthy diet is associated with less abdominal obesity (37). Nonetheless, 
uncertainty remains to whether the observed benefits of light wine consumption are due to 
wine itself or associated health behavior not controlled for in our study. Another study 
limitation was the inability to analyze effect modification by race, as the Finnish population 
is chiefly Caucasian. 
The diagnosis of hepatic steatosis was based on the FLI, which is surrogate rather than an 
absolute measure of liver fat. It is, however, a widely validated index, supported by the 
European Association for the Study of the Liver to be used in large population studies (9). 
The applicability of the FLI is further supported by the fact that the prevalence of hepatic 
steatosis (FLI ≥60) of 30% in our cohorts was very similar to that reported in previous 
Finnish studies using other diagnostic modalities (38). A limitation was our inability to study 
the impact of severity of liver fibrosis or steatohepatitis on outcomes. 
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Previous studies on liver outcomes 
No prospective trial on low to moderate alcohol use in NAFLD exists, and current evidence 
therefore relies on observational studies. In the general population not specific to NAFLD, 
alcohol intake as low as 12-20 g per day has been associated with increased risk for liver 
disease (39). However, these studies typically failed to adjust for metabolic factors and many 
were performed before the current NAFLD pandemic. In addition, many studies failed to 
consider non-fatal liver disease outcomes, which neglects a significant portion of clinically 
relevant liver events. 
 
Furthermore, in NAFLD, the impact of alcohol is more complex. Some cross-sectional 
studies on NAFLD subjects suggest that moderate alcohol use, as compared to abstinence, is 
associated with less advanced histological liver disease (12, 14-16). However, as recently 
reviewed (8), these studies are limited by major methodological concerns including the cross-
sectional design, incomplete adjustment for confounders, and statistical power. Cross-
sectional studies are unable to establish temporal relationship. In addition, various lifestyle 
factors may affect the pattern of alcohol use and thereby confound the observed associations. 
Most studies looked at the degree of liver fibrosis, but not clinical liver complications.  
One recent longitudinal study of 285 patients with biopsy-confirmed NAFLD found that 
alcohol intake of ≤2 drinks/day was associated with lower odds of histological steatohepatitis 
resolution compared to total abstinence (20). Longitudinal studies on subjects with advanced 
liver fibrosis or cirrhosis have moreover reported associations between low-moderate alcohol 
use and increased risks for hepatocellular carcinoma (40, 41), liver decompensation and liver-
related death (41). Although based on specific patient groups with advanced liver disease, 
these studies seem to support our finding that no safe limit of alcohol exists with regards to 
the risk for progression of liver disease in subjects with a fatty liver. 
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Previous studies on non-hepatic outcomes 
A 2006 meta-analysis (3) of 34 studies with 1015835 subjects and 94533 deaths found a J-
shaped relationship between alcohol use and all-cause mortality in the general population. In 
the studies with lifetime abstainers as the reference group, the maximal risk reduction of 
approximately 15% was seen at alcohol intake of 0-10 g/day with a significant risk reduction 
up to 30 g/day (3). This finding is well in line with our findings. Another meta-analysis found 
a similar J-shaped association between alcohol, especially wine, and CVD risk (31). The 
protective effect of low alcohol intake from CVD and death has been attributed to an 
improved insulin sensitivity and lipid profile, inhibition of platelet activation, reduction of 
fibrinogen level, and anti-inflammatory effects of alcohol (42, 43). Phenols and polyphenols 
in wine and beer are potential mediators (44). 
 
In the NAFLD population, one cross-sectional study found moderate alcohol use associated 
with decreased odds of having subclinical CVD, as compared to abstinence (45). This is in 
contrast with a more recent study with prospectively assessed alcohol consumption over time, 
which found no association between alcohol use and the presence of CVD risk factors or 
subclinical CVD (46). Nonetheless, clinical CVD events were not analyzed.  
 
A recent study based on the US population with 4568 subjects with NAFLD (defined by the 
hepatic steatosis index) found reduced mortality among subjects consuming 0.5-1.5 alcohol 
drinks/day, whereas >1.5 drinks/day became harmful, thus reinforcing a J-shaped association 
(47) . 
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In the general population, a number of studies link light to moderate alcohol intake with 
elevated risk for certain cancers (6, 7), similarly to that observed in our study on NAFLD 
subjects. 
 
Our findings may help in individualized counselling regarding alcohol intake for individuals 
with NAFLD. We found no evidence for appreciable harm from one glass of wine per day in 
non-smoking NAFLD patients, so this may not need to be prohibited in the average 
individual with NAFLD without advanced liver disease. In NAFLD with advanced liver 
disease or particular risk for progressive liver disease, however, complete alcohol abstinence 
seems warranted. The clinical implications of the J-shaped association between alcohol and 
incident CVD and death in never smokers remain unclear. From a holistic point of view, 
there are more effective and safer means to reduce CVD risk, and given the elevated risk 
estimates for liver disease and cancer, light to moderate alcohol drinking cannot be 
encouraged in NAFLD subjects. 
 
In conclusion, in subjects with fatty liver disease, even light consumption of non-wine 
alcohol beverages doubled the risk for future advanced liver disease. Moderate alcohol intake 
increased the overall risk for cancer. Alcohol intake was associated with a reduced risk for 
CVD events, and with a J-shaped association with all-cause mortality in non-smoking 
subjects.  
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Figure legends 
 
Figure 1. Flow chart of inclusion and exclusion criteria used to define the study population 
of subjects with a fatty liver. 
 
Figure 2. The relationship between average alcohol intake and risk for (panel A) advanced 
liver disease, (panel B) cardiovascular disease (CVD), (panel C) cancer, and (panel D) all-
cause death separately for men and women. Analyses are by Cox regression adjusted for the 
factors included in Model 3 of Table 2. Lifetime abstainers constitute the reference group and 
reference lines for men and women are displayed. The colored area represent 95% confidence 
intervals to the relative risk (hazards ratio) estimate. 
 
Figure 3. Interaction between alcohol intake (grams per day) and fraction of wine of total 
alcohol intake on the risk for incident advanced liver disease, cardiovascular disease (CVD), 
cancer, and all-cause mortality. Analyses are by Cox regression, and shows both age- and 
gender-adjusted analyses as well as multivariate analyses (adjusted for the factors included in 
Model 3 of Table 2). 
 
Figure 4. The relationship between average alcohol intake and risk for (A) cardiovascular 
disease (CVD) and (B) all-cause death according to smoking status. Analyses are by Cox 
regression adjusted for the factors included in Model 3 of Table 2. Lifetime abstainers 
constitute the reference group. The colored area represent 95% confidence intervals to the 
relative risk (hazards ratio) estimate. 
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Table 1. Baseline characteristics of individuals with a fatty liver. 
 
 
All subjects Men Women P 
Persons 8345 5048 3297 
 Age (years), mean (SD) 53.7 (12.6) 52.5 (12.3) 55.5 (12.9) <0.001 
Marital status, n (%) 
  
<0.001 
Married/partnership 6189 (74) 4027 (80) 2162 (66) 
 Single 2146 (26) 1016 (20) 1130 (40) 
 Education, n (%) 
  
<0.001 
Basic 3046 (37) 1673 (33) 1373 (42) 
 Secondary 2765 (33) 1753 (35) 1012 (31) 
 Higher 2449 (30) 1584 (32) 865 (27) 
 Employment status, n (%) 
  
<0.001 
Part- or full-time employed 4652 (56) 3104 (62) 1548 (47) 
 Retired 2866 (35) 1555 (31) 1311 (40) 
 Other 758 (9) 348 (7) 410 (13) 
 Alcohol consumption (g/day), n (%) 
 
<0.001 
Lifetime abstainer 993 (12) 272 (5) 721 (22) 
 0 - 9 4429 (53) 2353 (47) 2076 (63) 
 10 - 19 1448 (17) 1139 (23) 309 (9) 
 20 - 29 761 (9) 657 (13) 104 (3) 
 30 - 39 460 (6) 397 (8) 63 (2) 
 40 - 49 254 (3) 230 (4) 24 (1) 
 Percentage wine consumption of total 
alcohol consumption, mean (SD) * 23 (33) 17 (28) 37 (40) <0.001 
0 % 2933 (53) 2210 (57) 723 (42) 
 1-40% 1282 (23) 977 (26) 305 (18) 
 >40% 1357 (24) 667 (17) 690 (40) 
 Frequency of binge drinking, n (%) ** 
 
<0.001 
Weekly 673 (12) 579 (18) 94 (5) 
 Monthly 885 (17) 713 (22) 172 (8) 
 Less often or never 3752 (71) 1911 (60) 1841 (87) 
 Smoking status, n (%) 
  
<0.001 
Current 1941 (23) 1350 (27) 591 (18) 
 Former 2399 (29) 1818 (36) 581 (18) 
 Never 3967 (48) 1858 (37) 2109 (64) 
 Excercise, n (%) 
  
0.16 
At least 2 times a week 3613 (52) 2166 (51) 1447 (54) 
 2-4 times a month 1922 (28) 1182 (28) 740 (27) 
 Less often 1404 (20) 881 (21) 523 (19) 
 Body mass index (kg/m2), mean (SD) 31.5 (4.4) 30.3 (3.7) 33.3 (4.7) <0.001 
Waist circumference (cm), mean (SD) 105.0 (10.1) 106.0 (9.7) 103.4 (10.4) <0.001 
Diabetes, n (%) 1198 (14) 622 (12) 576 (18) <0.001 
Systolic blood pressure (mmHg), mean 
(SD) 141 (20) 141 (18) 142 (21) 0.36 
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Serum total cholesterol (mmol/L), mean 
(SD) 5.8 (1.1) 5.8 (1.2) 5.9 (1.1) 0.069 
Serum LDL cholesterol (mmol/L), mean 
(SD) 3.6 (1.0) 3.6 (1.0) 3.6 (1.0) 0.13 
Serum HDL cholesterol (mmol/L), mean 
(SD) 1.3 (0.3) 1.2 (0.3) 1.3 (0.4) <0.001 
Serum triglycerides (mmol/L), mean (SD) 2.1 (1.3) 2.3 (1.4) 2.0 (1.2) <0.001 
Glutamyltransferase (U/L), mean (SD) 53.0 (68.9) 56.8 (70.5) 47.0 (66.0) <0.001 
History of cardiovascular disease 514 (6) 394 (8) 120 (4) <0.001 
History of cancer 327 (4) 146 (3) 181 (6) <0.001 
Family history of CVD, n (%) 2815 (44) 1682 (41) 1133 (49) <0.001 
Family history of cancer, n (%) 1662 (34) 1000 (33) 662 (36) 0.024 
Finrisk score, mean (SD) 10.2 (15.0) 10.6 (15.2) 9.6 (14.8) <0.001 
Use of ASA, n (%) 
  
0.046 
In the past week 926 (19) 608 (19) 318 (17) 
 Earlier 364 (7) 214 (7) 150 (8) 
 Never 3719 (74) 2315 (74) 1404 (75) 
 Unknown 3336 (40) 1911 (38) 1425 (43) 
  
* Calculated for subjects reporting alcohol use (abstainers excluded) 
** Five or more alcohol portions per occasion (1 portion = 12 grams of ethanol) 
Abbreviations: ASA, acetylsalicylic acid; CVD, cardiovascular disease; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein 
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Table 2. Number of events, incidence rates and adjusted hazards ratios (HRs) by baseline 
alcohol intake for incident advanced liver disease, cardiovascular disease (CVD), cancer and 
all-cause death. HRs are calculated by Cox regression analysis with various level of 
adjustment (Model 1-3, see footnote). 
  Alcohol use (g/day)    
Liver outcome Lifetime 
abstainer 
0 - 9 10 - 19 20 - 29 30 - 39 40 - 49  
No. Events 13 59 25 22 16 17  
Age-adjusted incidence rate 
(per 100,000) 
94.0 123.0 148.7 250.9 333.2 570.8  
Age- and sex-adjusted HR 
(95% CI) 
Reference 1.34 (0.72-
2.49) 
2.16 (1.05-
4.46) 
3.67 (1.73-
7.78) 
4.71 (2.14-
10.40) 
9.53 (4.33-
21.00) 
Model 1 HR (95% CI) Reference 1.40 (0.74-
2.62) 
2.23 (1.06-
4.70) 
3.80 (1.76-
8.24) 
4.71 (2.09-
10.58) 
9.29 (4.16-
20.75) 
Model 2 HR (95% CI) Reference 1.37 (0.72-
2.59) 
2.24 (1.06-
4.75) 
3.83 (1.76-
8.35) 
4.61 (2.04-
10.43) 
9.34 (4.14-
21.09) 
Model 3 HR (95% CI) Reference 1.38 (0.74-
2.58) 
2.18 (1.05-
4.53) 
3.62 (1.69-
7.76) 
3.53 (1.53-
8.14) 
8.79 (3.95-
19.56) 
CVD outcomes       
No. Events 176 519 154 84 49 21  
Age-adjusted incidence rate 
(per 100,000) 
1139.5 1101.9 1123.1 1255.6 1191.9 1838.6  
Age- and sex-adjusted HR 
(95% CI) 
Reference 0.80 (0.67-
0.96) 
0.82 (0.65-
1.05) 
0.78 (0.59-
1.04) 
0.80 (0.59-
1.04) 
0.64 (0.40-
1.03) 
Model 1 HR (95% CI) Reference 0.88 (0.73-
1.06) 
0.93 (0.73-
1.19) 
0.88 (0.66-
1.17) 
0.87 (0.62-
1.22) 
0.71 (0.45-
1.14) 
Model 2 HR (95% CI) Reference 0.89 (0.74-
1.08) 
0.98 (0.76-
1.25) 
0.89 (0.66-
1.19) 
0.90 (0.64-
1.27) 
0.76 (0.47-
1.21) 
Model 3 HR (95% CI) Reference 0.78 (0.64-
0.95) 
0.78 (0.60-
1.01) 
0.71 (0.53-
0.97) 
0.71 (0.50-
1.00) 
0.60 (0.37-
0.96) 
Cancer       
No. Events 110 430 123 58 47 26  
Age-adjusted incidence rate 
(per 100,000) 
608.6 837.7 855.5 649.4 1235.3 2389.9  
Age- and sex-adjusted HR 
(95% CI) 
Reference 1.34 (1.07-
1.67) 
1.47 (1.11-
1.96) 
1.29 (0.91-
1.82) 
1.86 (1.29-
2.68) 
1.99 (1.27-
3.12) 
Model 1 HR (95% CI) Reference 1.25 (0.99-
1.58) 
1.34 (0.99-
1.81) 
1.16 (0.81-
1.65) 
1.64 (1.13-
2.40) 
1.77 (1.12-
2.80) 
Model 2 HR (95% CI) Reference 1.23 (0.97-
1.56) 
1.30 (0.96-
1.76) 
1.13 (0.79-
1.62) 
1.62 (1.11-
2.37) 
1.76 (1.11-
2.79) 
Model 3 HR (95% CI) Reference 1.24 (0.98-
1.57) 
1.31 (0.96-
1.77) 
1.14 (0.79-
1.63) 
1.58 (1.08-
2.32) 
1.75 (1.10-
2.79) 
All-cause death       
No. Events 260 554 150 81 63 34  
Age-adjusted incidence rate 1104.1 1026.9 956.4 1185.7 1440.9 1696.5  
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(per 100,000) 
Age- and sex-adjusted HR 
(95% CI) 
Reference 0.79 (0.67-
0.92) 
0.89 (0.70-
1.11) 
0.87 (0.66-
1.14) 
1.24 (0.92-
1.67) 
1.29 (0.89-
1.88) 
Model 1 HR (95% CI) Reference 0.73 (0.61-
0.86) 
0.75 (0.59-
0.96) 
0.71 (0.54-
0.95) 
1.00 (0.73-
1.35) 
1.03 (0.70-
1.51) 
Model 2 HR (95% CI) Reference 0.75 (0.63-
0.89) 
0.80 (0.63-
1.02) 
0.74 (0.55-
0.98) 
1.03 (0.76-
1.41) 
1.12 (0.76-
1.64) 
Model 3 HR (95% CI) Reference 0.79 (0.66-
0.95) 
0.87 (0.68-
1.11) 
0.79 (0.59-
1.06) 
1.05 (0.76-
1.45) 
1.20 (0.81-
1.77) 
Adjustments are for  
(A)  Liver events, in Model 1: age, sex, body mass index, smoking, exercise, and diabetes; 
in Model 2: Model 1 + employment, marital status and education; in Model 3: age, 
sex, employment, exercise, waist circumference, diabetes, systolic blood pressure, 
HDL cholesterol, glutamyltransferase and Finrisk score. 
(B) CVD events, in Model 1: age, sex, Finrisk score, ASA use, and exercise; in Model 2: 
Model 1 + employment, marital status and education; in Model 3: age, sex, ASA use, 
education, employment, smoking, exercise, waist circumference, diabetes, systolic 
blood pressure, total cholesterol, HDL cholesterol, triglyceride level, serum 
glutamyltransferase, and history of cancer. 
(C) Cancer, in Model 1: age, sex, smoking, body mass index, ASA use, exercise, diabetes, 
and family history of cancer; in Model 2: Model 1 + employment, marital status and 
education; in Model 3: age, sex, ASA use, marital status, education, employment, 
smoking, exercise, waist circumference, diabetes, systolic blood pressure, total 
cholesterol, triglyceride level, family history of cancer, and history of CVD. 
(D) All-cause death, in Model 1: age, sex, smoking, exercise, diabetes, body mass index, 
systolic blood pressure, and total cholesterol; in Model 2: Model 1 + employment, 
marital status and education; in Model 3: age, sex, marital status, education, 
employment, smoking, exercise, body mass index, waist circumference, diabetes, 
systolic blood pressure, ASA use, serum glutamyltransferase, history of cancer, and 
history of CVD.  
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